'Per­fect time': SIGA's CEO on re­tire­ment; Ju­ve­nes­cence woos GSK vet to lead an­ti-ag­ing play

In the 1990s, Phil Gomez re­calls the UK gov­ern­ment launch­ing what would be akin to a qua­si-Op­er­a­tion Warp Speed in to­day’s par­lance, as the re­gion was fac­ing high cas­es of menin­gi­tis C in chil­dren un­der the age of 5.

The chem­i­cal en­gi­neer by train­ing was work­ing at North Amer­i­can Vac­cine and helped the com­pa­ny launch a jab to help cur­tail the toll in the UK. He grew an ap­pre­ci­a­tion for pub­lic-pri­vate part­ner­ships, es­pe­cial­ly when na­tion­al gov­ern­ments and the bio­phar­ma and vac­cine man­u­fac­tur­ing in­dus­tries align.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN